[go: up one dir, main page]

FR2722411B1 - IMMUNONANOPARTICLES COATED WITH ANTI-BETA2 MICROGLOBULIN MONOCLONAL ANTIBODIES AND THEIR USE FOR PROPHYLAXIS AND / OR THE TREATMENT OF PATHOLOGIES DUE TO HIV VIRUS INFECTION - Google Patents

IMMUNONANOPARTICLES COATED WITH ANTI-BETA2 MICROGLOBULIN MONOCLONAL ANTIBODIES AND THEIR USE FOR PROPHYLAXIS AND / OR THE TREATMENT OF PATHOLOGIES DUE TO HIV VIRUS INFECTION

Info

Publication number
FR2722411B1
FR2722411B1 FR9408852A FR9408852A FR2722411B1 FR 2722411 B1 FR2722411 B1 FR 2722411B1 FR 9408852 A FR9408852 A FR 9408852A FR 9408852 A FR9408852 A FR 9408852A FR 2722411 B1 FR2722411 B1 FR 2722411B1
Authority
FR
France
Prior art keywords
immunonanoparticles
prophylaxis
coated
treatment
monoclonal antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR9408852A
Other languages
French (fr)
Other versions
FR2722411A1 (en
Inventor
Magniez Nicole Bru
Jean Claude Chermann
Francois Lescure
Jean Marie Charles Teulon
Pascal Breton
Xavier Guillon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UNION PHARMA SCIENT APPL
Institut National de la Sante et de la Recherche Medicale INSERM
UPSA SAS
Original Assignee
UNION PHARMA SCIENT APPL
Institut National de la Sante et de la Recherche Medicale INSERM
UPSA SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by UNION PHARMA SCIENT APPL, Institut National de la Sante et de la Recherche Medicale INSERM, UPSA SAS filed Critical UNION PHARMA SCIENT APPL
Priority to FR9408852A priority Critical patent/FR2722411B1/en
Priority to PCT/FR1995/000960 priority patent/WO1996002278A1/en
Priority to AU30798/95A priority patent/AU3079895A/en
Publication of FR2722411A1 publication Critical patent/FR2722411A1/en
Application granted granted Critical
Publication of FR2722411B1 publication Critical patent/FR2722411B1/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51Nanocapsules; Nanoparticles
    • A61K9/5107Excipients; Inactive ingredients
    • A61K9/513Organic macromolecular compounds; Dendrimers
    • A61K9/5138Organic macromolecular compounds; Dendrimers obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A61K47/6931Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer
    • A61K47/6933Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer the polymer being obtained by reactions only involving carbon to carbon, e.g. poly(meth)acrylate, polystyrene, polyvinylpyrrolidone or polyvinylalcohol
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nanotechnology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Biomedical Technology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Optics & Photonics (AREA)
  • Cell Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
FR9408852A 1994-07-18 1994-07-18 IMMUNONANOPARTICLES COATED WITH ANTI-BETA2 MICROGLOBULIN MONOCLONAL ANTIBODIES AND THEIR USE FOR PROPHYLAXIS AND / OR THE TREATMENT OF PATHOLOGIES DUE TO HIV VIRUS INFECTION Expired - Fee Related FR2722411B1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
FR9408852A FR2722411B1 (en) 1994-07-18 1994-07-18 IMMUNONANOPARTICLES COATED WITH ANTI-BETA2 MICROGLOBULIN MONOCLONAL ANTIBODIES AND THEIR USE FOR PROPHYLAXIS AND / OR THE TREATMENT OF PATHOLOGIES DUE TO HIV VIRUS INFECTION
PCT/FR1995/000960 WO1996002278A1 (en) 1994-07-18 1995-07-18 Immunonanoparticles coated with anti-beta-2 microglobulin monoclonal antibodies
AU30798/95A AU3079895A (en) 1994-07-18 1995-07-18 Immunonanoparticles coated with anti-beta-2 microglobulin monoclonal antibodies

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9408852A FR2722411B1 (en) 1994-07-18 1994-07-18 IMMUNONANOPARTICLES COATED WITH ANTI-BETA2 MICROGLOBULIN MONOCLONAL ANTIBODIES AND THEIR USE FOR PROPHYLAXIS AND / OR THE TREATMENT OF PATHOLOGIES DUE TO HIV VIRUS INFECTION

Publications (2)

Publication Number Publication Date
FR2722411A1 FR2722411A1 (en) 1996-01-19
FR2722411B1 true FR2722411B1 (en) 1996-10-04

Family

ID=9465475

Family Applications (1)

Application Number Title Priority Date Filing Date
FR9408852A Expired - Fee Related FR2722411B1 (en) 1994-07-18 1994-07-18 IMMUNONANOPARTICLES COATED WITH ANTI-BETA2 MICROGLOBULIN MONOCLONAL ANTIBODIES AND THEIR USE FOR PROPHYLAXIS AND / OR THE TREATMENT OF PATHOLOGIES DUE TO HIV VIRUS INFECTION

Country Status (3)

Country Link
AU (1) AU3079895A (en)
FR (1) FR2722411B1 (en)
WO (1) WO1996002278A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6750298B1 (en) * 1998-01-29 2004-06-15 Virsol Surfactant copolymers based on methylidene malonate

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2755136B1 (en) * 1996-10-25 1999-01-22 Virsol PROCESS FOR THE PREPARATION OF METHYLIDENE MALONATE NANOPARTICLES, NANOPARTICLES CONTAINING ONE OR MORE BIOLOGICALLY ACTIVE MOLECULES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
FR2789314B1 (en) * 1999-02-09 2001-04-27 Virsol WOUND SUTURE MATERIAL BASED ON METHYLIDENE MALONATE
AU2016265948B2 (en) 2015-05-18 2018-12-06 Alkahest, Inc. Methods and compositions for treating aging-associated impairments
CN109666072B (en) * 2018-12-28 2022-04-05 江苏众红生物工程创药研究院有限公司 Anti-human beta2-microglobulin antibodies and uses thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4264766A (en) * 1877-09-19 1981-04-28 Hoffmann-La Roche Inc. Immunological diagnostic reagents
JPH06504274A (en) * 1991-01-07 1994-05-19 シンジェニックス・リミテッド fine particles
AU6681494A (en) * 1993-04-22 1994-11-08 Institut National De La Sante Et De La Recherche Medicale Immunoparticles bearing monoclonal anti-cd4 antibodies and utilisation thereof

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6750298B1 (en) * 1998-01-29 2004-06-15 Virsol Surfactant copolymers based on methylidene malonate

Also Published As

Publication number Publication date
WO1996002278A1 (en) 1996-02-01
AU3079895A (en) 1996-02-16
FR2722411A1 (en) 1996-01-19

Similar Documents

Publication Publication Date Title
OA09498A (en) "Use of baclofen for obtaining medicaments intended for the treatment of angina pectoris".
BE851328A (en) COMPOSITION FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA
MA19428A1 (en) Orthopedic support and support vest for the treatment of trauma and operations on the shoulder, shoulder girdle and upper limb
DZ1877A1 (en) Dosage form of azithromycin for the treatment of microbial infections.
KR890002547A (en) Monoclonal antibodies and peptides for the treatment and diagnosis of HIV infection
DZ1334A1 (en) Use of a composition for the surface treatment of floors.
FR2684554B1 (en) MEDICINES FOR THE TREATMENT OF INFLAMMATORY CONDITIONS OR FOR ANALGESIA.
FR2751658B1 (en) USE OF A LIGAND CHEMOKINE (SDF-1) FOR LESTR / FUSIN / CXCR4 RECEPTOR TO PREVENT OR TREAT INFECTION WITH HIV-LIKE VIRUSES
FR2722411B1 (en) IMMUNONANOPARTICLES COATED WITH ANTI-BETA2 MICROGLOBULIN MONOCLONAL ANTIBODIES AND THEIR USE FOR PROPHYLAXIS AND / OR THE TREATMENT OF PATHOLOGIES DUE TO HIV VIRUS INFECTION
FI944561A0 (en) HIV-neutralizing recombinant human monoclonal antibodies for the prevention and treatment of HIV infection
FR2693129B1 (en) Tools for the electrochemical treatment of the internal surface of a tube.
FR2758465B1 (en) COMPOSITION FOR THE TREATMENT OF ASBESTOS
FR2340737A1 (en) COMPOSITION FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA
FR2704227B1 (en) IMMUNONANOPARTICLES CARRIING MONOCLONAL ANTI-CD4 ANTIBODIES AND THEIR USE FOR PROPHYLAXIS AND / OR THE TREATMENT OF CONDITIONS DUE TO HIV VIRUS INFECTION.
FR2737110B1 (en) USE OF MONOCARBOXYLIC ACIDS FOR THE TREATMENT OF KERATINIC MATERIALS
FR2718024B1 (en) Medicine and pharmaceutical composition for the treatment of inflammation.
FR2728161B1 (en) ORTHESIS DEVICE FOR THE TREATMENT OF HALLUX VALGUS
FR2636229B1 (en) ELBOW SUPPORT FOR THE TREATMENT OF EPICONDYLITIS AND EPITROCHLEITIS
OA06284A (en) Process for the preparation of compositions for the treatment of chronic infections of trypanosomiasis.
BE894228A (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF ATHEROSCLEROSIS
EP0655919A4 (en) TREATMENT OF VIRAL INFECTIONS IN MAN.
FR2537710B1 (en) INPUT STRUCTURE FOR ROTARY DRUMS FOR THE HEAT TREATMENT OF MATERIALS
FR2578425B1 (en) IMMUNOGLOBULIN PREPARATIONS HAVING HIGH TITLES OF ANTI-ALLERGENIC BLOCKING ANTIBODIES, THEIR PREPARATION AND THEIR APPLICATIONS FOR THE TREATMENT OF ALLERGIES
FR2686246B3 (en) WRIST ORTHOSIS FOR THE TREATMENT OF EPICONDYLALGIA.
FR2713087B1 (en) Use of selegiline and its derivatives for the preparation of a medicament intended for the treatment of psoriasis.

Legal Events

Date Code Title Description
ST Notification of lapse